Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-free antiviral treatment for HCV-associated indolent B-cell lymphoma
2015-004830-81Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ledipasvir, sofosbuvir and velpatasvir in hepatitis C virus infection and mature B-cell lymphoma (2 cohorts), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Sustained virologic response at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
ledipasvirsofosbuvirvelpatasvir
03
Conditions
hepatitis C virus infectionmature B-cell lymphoma
Beyond the preview
Go deeper on 2015-004830-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004830-81.